Biotech “Survivor”: Xoma (XOMA) Down 29% on Diabetes Drug Failure in Mid-Stage Study
But Cardiovascular Biomarker Indicates Anti-Inflammatory Activity For XOMA052 Xoma (XOMA $3.55) said its lead Type 2 diabetes drug-XOMA052- in a Phase 2b study failed to meet its main goal of lowering blood glucose levels. The trial failed to achieve its primary endpoint of reduction in...
Rayno Life Science Portfolio: Celera (CRA) up 29% on Buyout
Quest Diagnostics said today it would buy the diagnostics company Celera (CRA $8.10) for $671M.Celera business momentum had stalled in 2010 with Q4 Revenue down 11% at $34.9M with Net Income at 3 cents a share down from 4 cents a share in Q4 2009. Results from Celera's acquisition of Berkeley...
Nat Gas Rallies on Nuclear Concerns:Solid Move to $4.15
Price Action More Bullish in a Bear Market Interest perked up again on nat gas chat and how it deserves more respect in US energy policy. The latest commentary postulates a shift from nukes to gas fired plants over the longer term due to increased costs caused by safety and regulatory concerns....
Cepheid(CPHD $26) up 3% on Oppenheimer Outperform
M&A Target?? Molecular diagnostic device maker was a mover today on low volume with an analyst initiation at outperform.The stock is near its recent 52 week high of $27.79. Cepheid is an emerging growth leader in molecular diagnostics with its GeneXpert platform that performs diagnostic...
Biotech Stocks Down 1% But Winners Up On News:Cardiovascular Systems,Osirus, Incyte and Seattle Genetics
Volatile Day on Wall Street-Biotech Stocks Are Holding Up Well with NASDAQ Down 1.18% Selected biotech stocks were in the green today responding to good news despite a nasty day in the market. The major ETF's were down FBT ($38 down 1.09%), IBB ($94.25 down 0.8%), and XBI ($62.3 down 0.96%)....